MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Let’s Talk Medtech

Drop the 'Remote', It's Just Patient Monitoring

Image Courtesy of BioIntellisense IMG_2022-10-6-125920.jpg
Dr. Jim Mault, BioIntelliSense CEO, breaks down the rise of remote patient monitoring and explains why it’s time to drop the term for this episode of Let's Talk Medtech.


Remote patient monitoring has been around for some years now, but the pandemic helped catapult the sector to the forefront.

The forecast for the remote patient monitoring market shows that it’s expected to reach $175 billion by 2027 from $53.6 billion in 2022 during the forecast period, according to a report from Markets and Markets.

It’s a market that BioIntelliSense is making an impact in. The firm has developed the BioButton, multi-parameter wearable device and advanced data services for continuous vital sign monitoring.

Jim Mault, MD, BioIntelliSense CEO and founder spoke about the rise of the market and why remote patient monitoring is a misnomer in this all-new episode of Let’s Talk Medtech.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.